Hervycta

What is Hervycta?

Hervycta is the brand name for Trastuzumab, a biosimilar of the reference product Herceptin. It is primarily used in the treatment of HER2-positive cancers. Hervycta is designed to deliver comparable efficacy and safety to the reference product, offering a cost-effective option to improve access to advanced cancer therapies.

Visit Website

Storage Conditions

2-8 degrees Celsius (refrigerate),Do not freeze.

Presentation

Vial containing lyophilised powder for infusion + Bacteriostatic water for diluent.

Route of Administration

Intravenous (IV) (upon prescription only and administered by a healthcare provider.)

Indications

HER2-Positive Early Breast Cancer (EBC):

EBC is an aggressive type with a higher risk of recurrence. Hervycta is used after surgery and chemotherapy to reduce recurrence and improve survival.

How Trastuzumab works?

Mechanism of Action

Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed on the surface of certain cancer cells, particularly in HER2-positive breast cancer. It works by binding to the extracellular domain of the HER2 receptor, inhibiting the signaling pathways that promote cell proliferation and survival. Additionally, trastuzumab activates antibody-dependent cellular cytotoxicity (ADCC), a process where immune cells are recruited to destroy the HER2-positive cancer cells. This dual action - blocking HER2 signalling and enhancing immune cell-mediated destruction -helps to reduce tumour growth and is the basis for trastuzumab’s therapeutic efficacy in treating HER2-positive cancers.